NCT00227994View on ClinicalTrials.gov

Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

January 31, 2005

Study Completion Date

March 31, 2005

Conditions
Cerebrovascular Accident
Interventions
DRUG

Galantamine

Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.

DRUG

Donepezil

Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.

Trial Locations (1)

15260

University of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Pittsburgh

OTHER

NCT00227994 - Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke | Biotech Hunter | Biotech Hunter